Shaheen, Collins Issue Joint Statement on Eli Lilly's Decision to Cut Insulin Costs
March 02, 2023
March 02, 2023
WASHINGTON, March 2 -- Sen. Jeanne Shaheen, D-New Hampshire, issued the following news release:
U.S. Senators Jeanne Shaheen (D-NH) and Susan Collins (R-ME), co-chairs of the Senate Diabetes Caucus, issued the following statement in response to drugmaker Eli Lilly and Company (Lilly)'s announcement that it will cut the list prices for its commonly prescribed insulin medication by 70% and take additional steps to bolster affordability for diabetes patients. The company stated the 70% . . .
U.S. Senators Jeanne Shaheen (D-NH) and Susan Collins (R-ME), co-chairs of the Senate Diabetes Caucus, issued the following statement in response to drugmaker Eli Lilly and Company (Lilly)'s announcement that it will cut the list prices for its commonly prescribed insulin medication by 70% and take additional steps to bolster affordability for diabetes patients. The company stated the 70% . . .